Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | FER | P16591 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153349 | 1.00 | TRPA1 (0.45) | TRPA1EPHX1SYKCTSSCTSK | |
| SCHEMBL791254 | 0.80 | TRPA1 (0.45) | TRPA1EPHX1CTSSCTSKMAOA | |
| SCHEMBL4437198 | 0.77 | SYK (0.50) | SYKNPC1RAB9AKCNH2FER | |
| SCHEMBL5613415 | 0.77 | SYK (0.50) | SYKNPC1RAB9AKCNH2FER | |
| SCHEMBL5605298 | 0.77 | SYK (0.50) | SYKNPC1RAB9AKCNH2FER | |
| SCHEMBL1077404 | 0.77 | SYK (0.50) | SYKNPC1RAB9AKCNH2FER | |
| SCHEMBL15970604 | 0.77 | FER (0.41) | TRPA1SYKMAOAMAOBFER | |
| SCHEMBL7020150 | 0.77 | ALDH1A1 (0.51) | SYKCDK1FER | |
| SCHEMBL4064611 | 0.77 | ALDH1A1 (0.51) | SYKCDK1FER | |
| SCHEMBL4065551 | 0.77 | ALDH1A1 (0.51) | SYKCDK1FER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1597215-A1 | MONO AMINE AND DIAMINE DERIVATIVES OF CL-20 | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004076383-A9 | MONO AMINE AND DIAMINE DERIVATIVES OF CL-20 | SECR DEFENCE (GB) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004076383-A1 | MONO AMINE AND DIAMINE DERIVATIVES OF CL-20 | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | TRPA1 691/4885EPHX1 1073/4885SYK 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.